Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancer.

Date publication

mai 2026

Journal

Journal of the National Cancer Institute

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Raimondi A, Tinè G, Boige V, Ballhausen A, Gourgou S, Stahler A, Randon G, Manca P, Brument E, Alig AHS, Morano F, Prisciandaro M, Ambrosini M, Fazio R, Zhu Y, Miceli R, Bouche O, Modest DP, Pietrantonio F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42178223

Résumé

Doublet chemotherapy plus anti-EGFR is a standard of care in left-sided, microsatellite stable, RAS/BRAF wt (wt) mCRC. Guidelines recommend treatment de-escalation after achieving disease control with induction. Maintenance and intermittent (stop&go) strategies were investigated but not directly compared.

Mots clés

Anti-EGFR therapy, Intermittent treatment, Maintenance treatment, Meta-analysis, Metastatic colorectal cancer

Référence

J Natl Cancer Inst. 2026 05 22;: